Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
With a market cap of 121.66B, Bristol-Myers Squibb(BMY) trades at $59.71. The stock has a price-to-earnings ratio of 13.15 and currently yields dividends of 4.20%.
On 2026-10-09, Bristol-Myers Squibb(BMY) stock traded between a low of $58.73 and a high of $60.06. Shares are currently priced at $59.71, which is +1.7% above the low and -0.6% below the high.
Bristol-Myers Squibb(BMY) shares are trading with a volume of 13.07M, against a daily average of 13.04M.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.
BMY News
...
Bristol Myers Squibb & Co. (NYSE:BMY) announced topline results from its Phase 3 EXCALIBER-RRMM study on Thursday. The pharmaceutical company revealed its drug...
Bristol-Myers Squibb recently secured an expanded U.S. FDA approval for CAMZYOS for symptomatic obstructive hypertrophic cardiomyopathy across adults and eligib...
Analyst ratings
58%
of 31 ratingsMore BMY News
Bristol Myers (BMY Quick QuoteBMY - Free Report) is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line g...
Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediat...
An announcement from Immunome ( (IMNM) ) is now available. On October 2, 2026, Immunome, Inc. amended its long-standing license agreement with Bristol-Myers Sq...
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop t...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.